scholarly journals Mebeverine Hydrochloride Loaded Chitosan Microspheres as Potential Treatment Targeting Irritable Bowel Syndrome: Box-Behnken Design Optimization

2020 ◽  
Vol 10 (3) ◽  
pp. 326-331
Author(s):  
Azza Ali Hasan ◽  
Rasha Mohamed Samir ◽  
Samir Sayed Abu-Zaid ◽  
Amr Selim Abu Lila
Keyword(s):  
Irritable Bowel Syndrome ◽  
Design Optimization ◽  
Potential Treatment ◽  
Box Behnken Design ◽  
Chitosan Microspheres ◽  
Mebeverine Hydrochloride ◽  
Irritable Bowel ◽  
Treatment Targeting

scholarly journals An Efficient Synthesis of Anti-spasmodic Drug Mebeverine Hydrochloride

2021 ◽  
pp. 325-331
Author(s):  
V. S. R. N. Phanikumar ◽  
G. Veera Raghava Sharma
Keyword(s):  
Irritable Bowel Syndrome ◽  
Active Pharmaceutical Ingredient ◽  
Synthetic Route ◽  
Efficient Synthesis ◽  
Synthetic Process ◽  
Mebeverine Hydrochloride ◽  
Commercial Process ◽  
Three Stages ◽  
Irritable Bowel

An efficient synthetic process for an antispasmodic drug and active pharmaceutical ingredient of Mebeverine hydrochloride 1 is reported in this communication. It is used for stomach cramps and irritable bowel syndrome (IBS). The treatment for irritable bowel syndrome involves lot of drugs like (Dicyclomine hydrochloride, Linaclotide.etc) available in market, but Mebeverine hydrochloride (1) is most effective than any other drug. Earlier manufacturing 1 process reported yield < 46% and used high volumes of reagents and expensive catalyst. We developed new commercial process for 1 with economically, environmentally favored conditions. Proposed synthetic route contains three stages with overall yield of 77% and Purity by HPLC NLT 99.7%.

Treatment of Idiopathic Chronic Constipation and Irritable Bowel Syndrome with Constipation: What Role for Lubiprostone?

2010 ◽  
Vol 2 ◽  
pp. CMT.S5201
Author(s):  
Emily M. Ambizas ◽  
Priti N. Patel
Keyword(s):  
Irritable Bowel Syndrome ◽  
Chloride Channel ◽  
Chronic Constipation ◽  
Chronic Conditions ◽  
Treatment Options ◽  
Adult Women ◽  
Potential Treatment ◽  
Drug Reactions ◽  
Idiopathic Constipation ◽  
Irritable Bowel

Lubiprostone is a novel chloride channel 2 activator indicated for the treatment of chronic idiopathic constipation in adults and constipation-predominant irritable bowel syndrome (IBS-C) in adult women. It is effective for chronic constipation at a dose of 24 mcg twice daily and for IBS-C at a dose of 8 mcg twice daily. Lubiprostone is well-tolerated, with nausea and headache being the most commonly reported adverse drug reactions. It also has a low potential for drug-drug interactions. Lubiprostone is a potential treatment for both disorders, which have few treatment options available. Studies of longer duration will help more firmly establish its use for these chronic conditions.

Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome

2011 ◽  
Vol 21 (1) ◽  
pp. 58-61 ◽  
Author(s):  
David D. Manning ◽  
Christopher L. Cioffi ◽  
Alexander Usyatinsky ◽  
Kevin Fitzpatrick ◽  
Liaqat Masih ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Potential Treatment ◽  
Partial Agonists ◽  
Irritable Bowel ◽  
Type 3

Mediators of change in cognitive behaviour therapy and mebeverine for irritable bowel syndrome

2011 ◽  
Vol 41 (12) ◽  
pp. 2669-2679 ◽  
Author(s):  
S. E. Reme ◽  
D. Stahl ◽  
T. Kennedy ◽  
R. Jones ◽  
S. Darnley ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Theoretical Model ◽  
Social Adjustment ◽  
Behaviour Therapy ◽  
Path Analyses ◽  
Cognitive Behaviour ◽  
Mebeverine Hydrochloride ◽  
Behavioural Factors ◽  
Irritable Bowel ◽  
Best Fit

BackgroundCognitive behaviour therapies (CBTs) have through several trials been demonstrated to reduce symptoms and disability in irritable bowel syndrome (IBS) patients, but the mechanisms responsible for the changes are still unknown. The aim of this study was to test a theoretical model of CBT and investigate if cognitions and/or behaviour mediated the changes seen in CBT for IBS.MethodTo assess for possible mediating effects, we applied path analysis to the dataset of 149 diagnosed participants randomized to mebeverine hydrochloride plus CBT or mebeverine hydrochloride alone. Primary outcome was symptom severity, while secondary outcomes were work and social adjustment and anxiety.ResultsThe path analyses supported mediational paths for all outcomes. Changes in behaviour and cognitions mediated all three outcomes, with models placing behaviour change ‘upstream’ of cognition change having best fit. The analyses of model fits revealed best fit for the anxiety model and hence provide increased confidence in the causal model of anxiety.ConclusionsChanges in behaviour and cognitions mediate the change in CBT given to IBS patients. The results strengthen the validity of a theoretical model of CBT by confirming the interaction of cognitive, emotional and behavioural factors in IBS.

scholarly journals Efficacy and safety of Lactobacillus paracasei CNCM I-1572 and fructo- oligosaccharides in the treatment of patients with irritable bowel syndrome with constipation

2021 ◽  
Vol 1 (6) ◽  
pp. 57-62
Author(s):  
I. B. Khlinov ◽  
R. I. Khlynova ◽  
E. I. Voronova ◽  
E. V. Garanina ◽  
I. A. Gurikova ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Clinical Remission ◽  
Controlled Trial ◽  
Main Group ◽  
Lactobacillus Paracasei ◽  
Control Group ◽  
Treatment Regimens ◽  
Before And After ◽  
Mebeverine Hydrochloride ◽  
Irritable Bowel

The aim is to study the effect and safety of using the antispasmodic and synbiotic (Lactobacillus paracasei CNCM I-1572 in combination with fructooligosaccharides) in patients with irritable bowel syndrome with constipation.Materials and methods — prospective randomized controlled trial of 80 patients with irritable bowel syndrome with constipation. Patients in the main group (40 people) took mebeverine hydrochloride 200 mg 2 times a day and synbiotic (5x109 CFU Lactobacillus paracasei CNCM I-1572 and 5.2 g fructooligosaccharides) during 28 days. Patients in the control group (40 people) received mebeverine hydrochloride 200 mg 2 times a day during 28 days. Before and after treatment, patients underwent the GSPS questionnaire.Results — in control group clinical remission was achieved in 52.6% of patients. In the main group clinical remission was established in 92.3%, the increase was 39.7% (p <0.01). The relative risk of clinical remission when synbiotic included in the treatment for patients with irritable bowel syndrome with constipation is 1.75 (95% CI 1.28–2.4; p <0.01). When analyzing adverse events of the compared treatment regimens, no statistically significant differences were found (p = 0.75).Conclusion — the results of study demonstrate a significant increase in the effectiveness of therapy in patients with irritable bowel syndrome with constipation with the combined use of antispasmodic and synbiotic.

Sign in / Sign up

Export Citation Format

Share Document